NL8102827A - Werkwijze voor het maken van nieuwe mutanten van herpes simplexvirussen type 1 en type 2. - Google Patents

Werkwijze voor het maken van nieuwe mutanten van herpes simplexvirussen type 1 en type 2. Download PDF

Info

Publication number
NL8102827A
NL8102827A NL8102827A NL8102827A NL8102827A NL 8102827 A NL8102827 A NL 8102827A NL 8102827 A NL8102827 A NL 8102827A NL 8102827 A NL8102827 A NL 8102827A NL 8102827 A NL8102827 A NL 8102827A
Authority
NL
Netherlands
Prior art keywords
herpes
type
virus
viruses
mutants
Prior art date
Application number
NL8102827A
Other languages
English (en)
Dutch (nl)
Original Assignee
Asta Werke Ag Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Werke Ag Chem Fab filed Critical Asta Werke Ag Chem Fab
Publication of NL8102827A publication Critical patent/NL8102827A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16663—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NL8102827A 1980-06-12 1981-06-11 Werkwijze voor het maken van nieuwe mutanten van herpes simplexvirussen type 1 en type 2. NL8102827A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8019308 1980-06-12
GB8019308 1980-06-12

Publications (1)

Publication Number Publication Date
NL8102827A true NL8102827A (nl) 1982-01-04

Family

ID=10514018

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8102827A NL8102827A (nl) 1980-06-12 1981-06-11 Werkwijze voor het maken van nieuwe mutanten van herpes simplexvirussen type 1 en type 2.

Country Status (7)

Country Link
US (1) US4322404A (fr)
BE (1) BE889182A (fr)
DE (1) DE3122669A1 (fr)
ES (1) ES502965A0 (fr)
FR (1) FR2484446A1 (fr)
IT (1) IT8148649A0 (fr)
NL (1) NL8102827A (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554159A (en) * 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
GB8305323D0 (en) * 1983-02-25 1983-03-30 Baylor College Medicine Infectious bovine rhinotracheitis vaccine
NL8303501A (nl) * 1983-10-12 1985-05-01 Centraal Diergeneeskundig Inst Deletiemutant van een herpesvirus en vaccin, dat dit virus bevat.
USRE33772E (en) * 1983-10-12 1991-12-17 Centraal Diergeneeskundig Instituut Deletion mutant of a herpesvirus and vaccine containing said virus
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6471965B1 (en) * 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
US5837262A (en) * 1994-07-27 1998-11-17 Bio-Virus Research Incorporated Pharmaceutical compositions against several herpes virus infections and/or atherosclerotic plaque
CN101058800B (zh) * 2002-07-09 2013-03-13 巴克斯特国际有限公司 用于细胞培养的无动物蛋白质培养基

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR216081A1 (es) * 1976-07-02 1979-11-30 Dso Pharmachim Un metodo de preparar un mutante virosico avirulento a partir del virus de aujeszky
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung

Also Published As

Publication number Publication date
BE889182A (fr) 1981-12-11
ES8303522A1 (es) 1983-02-01
FR2484446A1 (fr) 1981-12-18
DE3122669A1 (de) 1982-02-11
IT8148649A0 (it) 1981-06-10
ES502965A0 (es) 1983-02-01
US4322404A (en) 1982-03-30

Similar Documents

Publication Publication Date Title
EP0020356B1 (fr) Vaccins contre la pasteurellose
Morein et al. Effective subunit vaccines against an enveloped animal virus
Zawatzky et al. The Role of Interferon in the Resistance of CS7BL/6 Mice to Various Doses of Herpes Simplex Virus Type 1
KR100186783B1 (ko) 적혈구와 표면-결합된 항원을 포함하는 경구용 백신
JP4709094B2 (ja) 病原性の低いｐｒｒｓ生ウイルスワクチン、ならびにその製造方法
Norrby The effect of a carbobenzoxy tripeptide on the biological activities of measles virus
Hitchcock et al. Protection of mice against the lethal action of an encephalitis virus
NL8102827A (nl) Werkwijze voor het maken van nieuwe mutanten van herpes simplexvirussen type 1 en type 2.
Harmon et al. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
US4315914A (en) Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
Klockmann et al. Preclinical investigations of the safety, immunogenicity and efficacy of a purified, inactivated tick-borne encephalitis vaccine
PT90310B (pt) Processo para a obtencao de preparacoes de adenilato-ciclase
CA1039187A (fr) Vaccin contre la leucemie feline
US9700615B2 (en) Adjuvant formulations and methods
IE46498B1 (en) New vaccine
US5460815A (en) Feline infectious peritonitis vaccine and method of preparation
JPS60146831A (ja) モラクセラ・ボビス・バクテリン
Raj et al. Cross‐reactive cellular immune responses in chickens vaccinated with live infectious bronchitis virus vaccine
Panse et al. Passive immunity in experimental cholera
EP0037441A1 (fr) Compositions pharmaceutiques utilisables comme immunostimulant cellulaire et comme agent anti-tumeur, procédé de préparation et microorganisme utilisé
Campbell et al. Present trends and the future in rabies research
Cameron Tile haemagglutination test and immunity to pasteurella haemolytica
Behbehani et al. Yaba tumor virus. I. Studies on pathogenesis and immunity
Babudieri et al. Comparative tests with formolized and irradiated vaccines against leptospirosis

Legal Events

Date Code Title Description
BV The patent application has lapsed